Patent for Nano-scale Detection of Ion Channel Function in Lipoparticles
News Feb 21, 2013
The U.S. patent covers the application of Integral Molecular’s Lipoparticle technology for deriving high concentrations of functional ion channels for drug screening, antibody development, and biomedical research. Ion channels are important therapeutic targets for a wide range of human diseases and comprise approximately 15% of existing drug targets. Lipoparticle technology stems from research conducted at the University of Pennsylvania and published in the journals Science, PNAS, and Journal of Virology. US Patent No. 8,377,691 was issued by the U.S. Patent and Trademark Office on February 19, 2013 to Integral Molecular.
“The Lipoparticle technology overcomes many of the challenges of conventional electrophysiological approaches for screening ion channel targets, which have largely been limited to studies with live cells or reconstituted lipid bilayers,” said Dr. Benjamin Doranz, Chief Scientific Officer at Integral Molecular and the inventor of the technology. “Development and validation of the Lipoparticle ion channel technology enabled Integral Molecular to successfully implement high-throughput screening (HTS) campaigns against ion channels, including the identification of novel anti-influenza lead compounds.”
Integral Molecular offers custom-produced Lipoparticles with user-specified membrane proteins, as well as ReadyReceptor® Lipoparticles that contain pre-validated high-concentration membrane protein targets such as GPCRs, transporters, and ion channels. Each lot of Lipoparticles is quality controlled and provided with technical protocols for relevant applications, including antibody screening, biosensor assays, ELISA binding assays, and functional assays. Lipoparticles can be biotinylated or fluorescently labeled to accommodate specialized applications.
Children With Congenital Zika Virus Infection Face Serious Challenges as They AgeNews
The report from the CDC is the first to describe the health and developmental effects of congenital Zika virus infection in children with microcephaly through 2 years of age.READ MORE
British Pharmacological Society’s Drug Discovery of the Year 2018 AnnouncedNews
A new medicine used to treat an ultra-rare inherited disorder which leaves babies without a fully functioning immune system has been named the British Pharmacological Society’s Drug Discovery of the Year 2018.READ MORE